Table 2.
Correlations of YAP1 protein expression and clinical and molecular parameters of the randomised cohort (n=500)
| |
All patients, n= 500 |
|
ER
+
patients, n=324 |
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| |
YAP1 intensity, n=324 |
|
YAP1 intensity, n=213 |
|
||||||
| |
Absent |
Weak |
Intermediate |
Strong |
p-value |
Absent |
Weak |
Intermediate |
Strong |
p-value |
| |
n (%) |
n (%) |
n (%) |
n (%) |
|
n (%) |
n (%) |
n (%) |
n (%) |
|
| Variable | 28 (9) | 130 (40) | 128 (39) | 38 (12) | 21 (10) | 95 (45) | 79 (37) | 18 (8) | ||
| NHG |
|
|
|
|
|
|
|
|
|
|
| I |
0 |
10 (8) |
11 (9) |
5 (13) |
|
0 |
10 (11) |
11 (14) |
5 (28) |
|
| II |
13 (48) |
55 (44) |
56 (45) |
10 (27) |
|
12 (57) |
48 (50) |
51 (65) |
9 (50) |
|
| III |
14 (52) |
60 (48) |
57 (46) |
22 (60) |
0.932a |
9 (43) |
37 (39) |
16 (21) |
4 (22) |
0.001a |
| Lymph node status |
|
|
|
|
|
|
|
|
|
|
| Negative |
7 (25) |
35 (27) |
34 (27) |
15 (41) |
|
5 (24) |
25 (26) |
19 (24) |
5 (29) |
|
| Positive |
21 (75) |
94 (73) |
94 (73) |
22 (59) |
0.285b |
16 (76) |
70 (74) |
60 (76) |
12 (71) |
0.971b |
| Tumour size |
|
|
|
|
|
|
|
|
|
|
| <20 mm |
12 (44) |
43 (33) |
46 (36) |
13 (34) |
|
10 (50) |
35 (37) |
33 (42) |
6 (33) |
|
| ≥20 mm |
15 (56) |
87 (67) |
82 (64) |
25 (66) |
0.815b |
10 (50) |
60 (63) |
46 (58) |
12 (67) |
0.757b |
| ERα |
|
|
|
|
|
|
|
|
|
|
| <10% |
4 (16) |
33 (26) |
46 (37) |
20 (53) |
|
- |
- |
- |
- |
|
| ≥10% |
21 (84) |
95 (74) |
79 (63) |
18 (47) |
<0.001b |
- |
- |
- |
- |
|
| PgR |
|
|
|
|
|
|
|
|
|
|
| <10% |
6 (24) |
35 (29) |
47 (39) |
20 (56) |
|
1 (5) |
6 (7) |
4 (5) |
0 |
|
| ≥10% |
19 (76) |
86 (71) |
75 (61) |
16 (44) |
0.002b |
18 (95) |
84 (93) |
73 (95) |
16 (100) |
0.464b |
| Ki-67 fraction (%) |
|
|
|
|
|
|
|
|
|
|
| 0-10 |
12 (48) |
48 (40) |
53 (45) |
10 (29) |
|
9 (47) |
37 (42) |
47 (64) |
9 (56) |
|
| 11-25 |
7 (28) |
38 (32) |
34 (29) |
7 (20) |
|
6 (32) |
30 (34) |
20 (27) |
3 (19) |
|
| 26-100 |
6 (24) |
34 (28) |
31 (26) |
18 (51) |
0.198a |
4 (21) |
21 (24) |
6 (8) |
4 (25) |
0.016a |
| Cyclin D1 intensity |
|
|
|
|
|
|
|
|
|
|
| absent/weak |
8 (31) |
67 (53) |
81 (67) |
29 (76) |
|
3 (14) |
39 (42) |
40 (51) |
9 (50) |
|
| intermediate/strong |
18 (69) |
59 (47) |
40 (33) |
9 (24) |
<0.001b |
18 (86) |
54 (58) |
38 (49) |
9 (50) |
0.010b |
|
CCND1 amplification |
|
|
|
|
|
|
|
|
|
|
| No |
8 (44) |
69 (84) |
75 (89) |
24 (96) |
|
5 (36) |
48 (80) |
47 (84) |
12 (92) |
|
| Yes | 10 (56) | 13 (16) | 9 (11) | 1 (4) | <0.001b | 9 (64) | 12 (20) | 9 (16) | 1 (8) | 0.003b |
NHG=Nottingham histological grade, ERα=estrogen receptor, PgR=progesterone receptor.
aSpearman´s rank correlation.
bMann-Whitney U test.